Ionian Technologies

Infobox_Company
company_name = Ionian Technologies Inc.

company_type = Private | company_slogan = Detect to Protect
foundation = 2000 Spinoff from Keck Graduate Institute
2001 incorporated
location = San Diego, California
key_people = John G. Watson, President & CEO
num_employees = 20 (2006)
industry = biotechnology company- Minor
products = None

revenue = profitNot Disclosed USD (2006)
operating_income = profit Not Disclosed USD (2005)
net_income = profit Not Disclosed USD (2005)
homepage = [http://www.ionian-tech.com/ www.ionian-tech.com] Ionian Technologies Inc. is a United States Biotechnology Company focused on molecular diagnostics development for the detection of infectious diseases and biothreat agents. It was established in 2000 in Upland, California as the first spin-off company to commercialize technology developed at the Keck Graduate Institute. Since its inception Ionian has expanded its isothermal amplification technology and currently is involved in contracts for the United States Department of Defense and Homeland Security.

History

Ionian traces its origins to Dr. David Galas who was previously Chancellor, Chief Scientific Officer and Norris Professor of Applied Life Science at the Keck Graduate Institute of Applied Life Sciences. During his development of KGI he spun off Ionian Technologies from work done in his lab, based upon a 2003 PNAS paper [cite journal
author=Van Ness, J., Van Ness, LK., Galas. | title=Isothermal reactions for the amplification of oligonucleotides | journal=Proc Natl Acad Sci USA | year=2003 | pages=6 | volume=100 | issue=8 | id= PMID 12679520 |format=] .

In 2001, Ionian was incorporated in Delaware.

Corporate governance

Current members of the board of directors of Ionian Technologies are: John G. Watson, David Galas, and Paul Tardif.

Mission

Ionian Technologies Inc. describes itself as a private company focused on molecular diagnostics and advanced biomedical research tools based on proprietary isothermal systems for DNA and RNA amplification and detection. This technology is being developed for infectious disease diagnostics and biothreat detection.Ionian is focused on providing rapid and economical systems for the expanding healthcare and biothreat markets.Ionian also claims that the technology provides for the amplification of nucleic acids, both DNA and RNA, in approximately 5 minutes. Even the fastest PCR reactions require ~30 minutes; hence, the technology provides a significant speed advantage compared to PCR. The amplification products can be detected using a variety of standard and proprietary methods. Ionian’s assay technology is therefore ideally suited for portable and handheld detectors and sensors.

ee also

*Keck Graduate Institute

External links

* [http://www.ionian-tech.com/About.html About Ionian Technologies]
* [http://www.ionian-tech.com/Careers.html Jobs at Ionian Technologies]
* [http://www.darpa.mil/sto/chembio/hisss.html Ionian’s DARPA Project]

Notes and references

=External links=

External links

{| class="toccolours" style="width: 100%; border-top: none;"